After failure of gemcitabine/docetaxel chemotherapy, next-generation sequencing identified an IGFBP5-ALK fusion (breakpoint: IGFBP5 exon 1 - ALK exon 19), a TERT promoter mutation, and a homozygous CDKN2A/CDKN2B/MTAP deletion. This case highlights the first documented response to an ALK inhibitor in ALK-rearranged HG-ESS. The findings underscore the importance of comprehensive molecular profiling in identifying targetable alterations in rare sarcomas and support the use of iruplinalkib as an effective therapeutic option in this setting.

1 day ago

Journal

ALK (Anaplastic lymphoma kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • BCOR (BCL6 Corepressor) • IGFBP5 (Insulin Like Growth Factor Binding Protein 5)

ALK positive • ALK rearrangement • ALK fusion • CDKN2A deletion • MTAP deletion

gemcitabine • docetaxel • Qi Xinke (iruplinalkib)

Treating Patients With Melanoma and ALK Alterations With Ensartinib (clinicaltrials.gov)

P2, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

2 days ago

Trial completion date • Trial primary completion date

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)

BRAF V600 • ALK fusion • ALK mutation

Ensacove (ensartinib)

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P3, N=71, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

3 days ago

Enrollment closed

PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ALK positive • ALK fusion • ROS1 fusion • ROS1 positive

PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay

Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib)

Genomic Characterization of Lung Cancer in Never-Smokers Using Deep Learning. (PubMed, Mod Pathol)

Compared to results from established architectures such as Inception-v3 on the same WSIs, our model demonstrated significantly improved performance for most features. With further optimization, our model could support triaging for molecular testing and inform precision treatment strategies for NS-LUAD patients.

3 days ago

Journal • Tumor mutational burden

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MDM2 (E3 ubiquitin protein ligase) • RBM10 (RNA Binding Motif Protein 10)

TP53 mutation • KRAS mutation • EGFR mutation • KRAS G12C • EGFR L858R • KRAS G12D • ALK fusion • CDKN2A deletion • KRAS G12

A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors. (PubMed, Genome Biol)

This study provides a comprehensive functional atlas of ALK tyrosine kinase domain variants under TKI selection, offering a valuable experimental framework for interpreting resistance-associated variants. Although derived from in vitro models and therefore context dependent, this resource complements existing clinical and genomic knowledge and may aid in the functional interpretation of ALK variants observed in ALK-driven cancers.

5 days ago

Journal

ALK (Anaplastic lymphoma kinase)

ALK fusion • ALK G1202R

Alecensa (alectinib) • Lorbrena (lorlatinib)

ALK-positive ALCL: first described adult case of synchronous CNS and systemic involvement at presentation: a case report and review of the literature. (PubMed, Br J Neurosurg)

The patient was treated with a modified MARIETTA protocol (without rituximab) and consolidated with a carmustine-based autologous stem cell transplant. shows complete metabolic response on PET-CT and MRI brain. This case presents the first successful treatment of a synchronous presentation of CNS and systemic ALK-positive ALCL, and the importance of a multidisciplinary approach for diagnosis.

7 days ago

Journal

ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)

ALK positive • ALK fusion • ALK translocation

Rituxan (rituximab) • carmustine

A Prospective Multicenter Study of Stereotactic Ablative Radiotherapy Combined with Immunotherapy for Early-Stage Non-Small Cell Lung Cancer (ChiCTR2600116150)

P=N/A, N=35, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

8 days ago

New trial

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

EGFR mutation • ALK fusion

A Single-Arm, Single-Center, Prospective Phase II Clinical Study of Stephania Longa and Jiezai Rice Combined with Sintilimab in Advanced Driver Gene-Negative, PD-L1-Positive NSCLC Patients Who Failed First-Line Immunotherapy (ChiCTR2500114858)

P=N/A, N=29, Recruiting, Hainan General Hospital; Hainan General Hospital

8 days ago

New trial

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • RET fusion • ALK fusion • ROS1 fusion

Tyvyt (sintilimab)

A randomized controlled clinical study on postoperative adjuvant targeted therapy and MRD observation for stage IA non-small cell lung cancer (ChiCTR2500112620)

P4, N=178, Not yet recruiting, Beijing chest hospital capital medical university; Beijing Chest Hospital Capital Medical University

8 days ago

New P4 trial

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

EGFR mutation • ALK positive • ALK fusion • ALK mutation • EGFR positive

Conmana (icotinib) • Ensacove (ensartinib)

A single-arm, multicenter clinical study of ensartinib combined with chemotherapy as neoadjuvant therapy for ALK-positive non-small cell lung cancer (NSCLC) (TD-ENSEMBLE study) (ChiCTR2500113689)

P4, N=20, Not yet recruiting, The Second Affiliated Hospital of Air Force Medical University; The Second Affiliated Hospital of Air Force Medical University

8 days ago

New P4 trial

ALK (Anaplastic lymphoma kinase)

ALK fusion • ALK mutation

Ensacove (ensartinib)

Study on the efficacy of Utidelone combined with Anotinib in the treatment of advanced Non-Small Cell Lung Cancer (ChiCTR2500115269)

P2, N=61, Not yet recruiting, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen Un

8 days ago

New P2 trial

ALK (Anaplastic lymphoma kinase)

EGFR mutation • ALK positive • ALK fusion

Focus V (anlotinib) • utidelone IV (UTD1)

An Open-Label, Single-Center, Multi-Cohort, Phase II Study Evaluating the Safety and Efficacy of Vebreltinib-Based Combination Therapy in Previously Treated Patients with Locally Advanced or Metastatic MET-Overexpressing Non-Small Cell Lung Cancer (ChiCTR2500112942)

P2, N=52, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University

8 days ago

New P2 trial

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • ALK rearrangement • MET exon 14 mutation • MET overexpression • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • MET mutation • MET expression • RET rearrangement • NTRK fusion

docetaxel • Jiataile (sacituzumab tirumotecan) • bozitinib (APL-101)